http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Biocept to Report Second Quarter 2021 Financial Results and Host Investor Conference Call on August 16, 2021
-
Biocept Names David Karlander as Senior Vice President of Commercial Operations
-
Biocept (BIOC) Announces Medicare Issues Local Coverage Determination for Target Selector Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells
-
Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells
-
Biocept (BIOC) Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman
-
Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman
-
Biocept to Participate in Two July Investment Conferences
-
Biocept (BIOC) Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers
-
Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers
-
Biocept Joins the Russell Microcap® Index
-
Biocept (BIOC) to Collaborate with Quest Diagnostics (DGX) to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer
-
Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer
-
Biocept Receives More Than 420,000 Samples During First Year of Offering COVID-19 Testing Service
-
Biocept and CLEARED4 Collaborate to Develop New Service for Managing COVID-19 Testing and Results Reporting for Biocept Customers
-
Biocept to Present at the LD Micro Virtual Invitational XI Conference on June 9, 2021
-
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Biocept Reports First Quarter 2021 Financial Results
-
Biocept to Report First Quarter 2021 Financial Results and Host Investor Conference Call on May 12, 2021
-
Biocept to Supply COVID-19 Testing Through Partnership With the Foundation for California Community Colleges
-
Biocept (BIOC) Announces Full Commercial Launch of CNSide Cerebrospinal Fluid Assay to Address Unmet Needs for Patients with Metastatic Brain Cancer
-
Biocept Announces Full Commercial Launch of CNSide™ Cerebrospinal Fluid Assay to Address Unmet Needs for Patients with Metastatic Brain Cancer
-
Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date
-
Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
-
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Biocept to Host Key Opinion Leader Webinar on April 8 to Discuss its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
-
Biocept Reports 2020 Fourth Quarter and Full Year Financial Results
-
Biocept to Report 2020 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 29, 2021
-
Biocept to Participate in Three Virtual Investment Conferences in March
-
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Aegea Biotechnologies Announces Supply Agreement with Biocept (BIOC) for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Loa
-
Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load
-
Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load
-
Biocept (BIOC) and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector Assay Kit for Non-Small Cell Lung Cancer Patients
-
Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients
-
Biocept (BIOC) Announces Study Shows its Target Selector Detects Mutations in “Quantity Not Sufficient” Specimens in Non-Small Cell Lung Cancer Patients
-
Study Shows Biocept’s Target Selector™ Detects Mutations in “Quantity Not Sufficient” Specimens in Non-Small Cell Lung Cancer Patients
-
Pre-Open Stock Movers 03/02: (FTSV) (TRIL) (TWTR) Higher; (BIOC) (ENLV) (NVAX) Lower (more...)
-
Biocept (BIOC) Enters Collaboration to Provide Liquid Biopsy Testing for Small Cell Lung Cancer Patients with Lambert Eaton Myasthenic Syndrome (LEMS)
-
Biocept and Catalyst Pharmaceuticals Collaborate to Provide Liquid Biopsy Testing for Small Cell Lung Cancer to Patients with Lambert Eaton Myasthenic Syndrome (LEMS)
-
Biocept (BIOC) Enters Agreement with PPO Network Prime Health Services
-
Biocept Secures Agreement with Preferred Provider Organization Prime Health Services
-
Unusual 11 Mid-Day Movers 2/6: (XLS) (ATV) (CBM) Higher; (RENT) (NKA) (ATNM) Lower

